A digital toolkit to contextualize and visualize the benefit and risk of COVID-19 vaccines in the European union

Abstract

partial year of 2022, the incidence of IOI was 0.026% (0.019, 0.032) and 0.034% (0.022, 0.047) with PFS and vials, respectively. The incidence of suspected endophthalmitis in 2020 and 2021, respectively, was 0.014% (0.09, 0.019) and 0.013% (0.09, 0.017) with PFS and 0.028% (0.020, 0.036) and 0.029% (0.020, 0.037) with vials. In the partial year of 2022, the incidence of suspected endophthalmitis was 0.016% (0.011, 0.021) with PFS and 0.020% (0.010, 0.029) with vials. Conclusions: Incidences of IOI and suspected endophthalmitis decreased from 2014 to the partial year of 2022. Incidences were lower with PFS than with vials in 2020 and 2021 with no conclusive difference in the partial year of 2022. 636 | Risk of venous thromboembolism with janus kinase inhibitors in rheumatoid arthritis: A systematic review